Skip to main content
SSO 2026 Annual Meeting Main banner

Melanoma

CME

TIL (tumor-infiltrating lymphocytes) Therapy for Advanced Melanoma: From Experimental to Standard Care

Friday, March 6, 2026
2:35 PM - 3:35 PM MST
Location:301A
CE: 1

We will discuss the development of TIL therapy and the data leading to TIL (lifileucel) becoming a standard-of-care option for patients with advanced melanoma. Surgeons play an essential part of the multidisciplinary team required for successful TIL therapy since surgical resection of a tumor for TIL harvest is the first but crucial step. Methods to optimize TIL harvest will be outlined. Lastly, we will present state-of-the-art developments in modified TIL therapy aiming to improve the clinical efficacy of TIL while decreasing side effects.

Learning Objectives:

  • Identify appropriate patients for TIL therapy.
  • Identify appropriate tumors for resection and methods to optimize tumor resection for TIL harvest.
  • Identify available ongoing clinical trials evaluating modified TIL therapy.

Presentations:

  • 2:38 PM - 2:53 PM MST
    TIL Therapy for Metastatic Melanoma

    Faculty: Amod Sarnaik, MD, FACS – Moffitt Cancer Center

  • 2:53 PM - 3:08 PM MST
    Optimization of TIL Harvest

    Faculty: Stephanie L. Goff, MD – Surgery Branch, National Cancer Institute

  • 3:08 PM - 3:23 PM MST
    Modified TIL and Future Developments

    Faculty: Allison Betof, MD, PhD (she/her/hers) – Stanford University

  • 3:23 PM - 3:35 PM MST
    Q&A and Closing Discussion: How does TIL Therapy fit in the Therapeutic Spectrum for Patients with Metastatic Melanoma